ClinConnect ClinConnect Logo
Search / Trial NCT00972049

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Launched by ASTRAZENECA · Sep 3, 2009

Trial Information

Current as of July 01, 2025

Completed

Keywords

Safety Tolerability Azd2516 Pain Japanese

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Weight between 45 to 100 kg and a body mass index (BMI) between 19 to 28 kg/m2
  • Japanese males aged between 20 to 45 years old (young) and Japanese males or females aged between 65 to 80 years old (elderly)
  • Exclusion Criteria:
  • History of previous or ongoing somatic or psychiatric disease/condition
  • Abnormalities in ECG that may interfere with interpretation of data.

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Fukuoka, , Japan

Patients applied

0 patients applied

Trial Officials

Anders Neijber, MD, PhD

Study Director

AstraZeneca R&D Södertälje

Shunji Matsuki, MD, PhD

Principal Investigator

Kyusyu Clinical Phramacology Research Clinic

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials